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Abstract
Background: Stereotactic radiosurgery/radiotherapy procedures are known to deliver a very high dose per fraction,
and thus, the corresponding peripheral dose could be a limiting factor for the long term surviving patients. The
aim of this clinical study was to measure the peripheral dose delivered to patients undergoing intracranial
Cyberknife treatment, using the MOSFET dosimeters. The influence of the supplemental shielding, the number of
monitor units and the collimator size to the peripheral dose were investigated.
Methods: MOSFET dosimeters were placed in preselected anatomical regions of the patient undergoing
Cyberknife treatment, namely the thyroid gland, the nipple, the umbilicus and the pubic symphysis.
Results: The mean peripheral doses before the supplemental shielding was added to the Cyberknife unit were
51.79 cGy, 13.31 cGy and 10.07 cGy while after the shielding upgrade they were 38.40 cGy, 10.94 cGy, and 8.69
cGy, in the thyroid gland, the umbilicus and the pubic symphysis, respectively. The increase of the collimator size
corresponds to an increase of the PD and becomes less significant at larger distances, indicating that at these
distances the PD is predominate due to the head leakage and collimator scatter.
Conclusion: Weighting the effect of the number of monitor units and the collimator size can be effectively used
during the optimization procedure in order to choose the most suitable treatment plan that will deliver the
maximum dose to the tumor, while being compatible with the dose constraints for the surrounding organs at risk.
Attention is required in defining the thyroid gland as a structure of avoidance in the treatment plan especially in
patients with benign diseases.
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Background
During all radiotherapy treatments, there is always a
small unavoidable fraction of the delivered dose that is
absorbed by radiosensitive tissues/organs outside the
irradiated volume, known as peripheral dose (PD). PD is
due to radiation that is scattered from the patients’ body,
the linac head components, the treatment room walls
and lastly, radiation leakage from the linac head. Stereo-
tactic radiosurgery/radiotherapy (SRS/SRT) procedures
main aim is to deliver a very high dose per fraction to the
target, and thus the corresponding PD outside the treat-
ment volume is an important issue, especially for the
long term surviving patients.
The main concern in a treatment plan is on how to
apply the maximum dose to the target, without exceeding
the dose constraints of the surrounding organs at risk.
These dose constraints, which are based on clinical stu-
dies, aim at minimizing side effects (normal tissue compli-
cations), which could even be the induction of secondary
cancer [1]. The risk for secondary cancer is of a main con-
cern especially in long term surviving patients, who are
treated for benign diseases or for curatively non metastatic
malignancies. Epidemiological evidence from human
populations demonstrate that organ doses above 5-10 cGy
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could increase the risk of some types of cancer [2].
The thyroid gland is a very radiosensitive organ that,
although is not the target during intracranial treatments, it
can be affected by scattered radiation [3]. Especially, in
young patients, it has been shown that there is a signifi-
cantly increased risk of cancer in the thyroid gland, after
exposure to radiation, as part of therapy in childhood can-
cers [4]. The breast is also one of the sensitive organs
regarding the carcinogenic effects of radiation, and there is
an excessive risk of secondary cancers being induced for
the breast even at doses as low as 1-9 cGy [2].
The Cyberknife is a frameless, image-guided, stereotactic
radiosurgery system with sub-millimeter clinical accuracy
[5]. The system comprises of a 6 MV linear accelerator
mounted on a robotic arm, along with an image guided
system. Through the image guidance cameras (which are
composed of a pair of orthogonal diagnostic x-ray tubes
and corresponding image detectors), specialized software,
which uses x-ray images obtained throughout the treat-
ment, verifies the patient position, based on radiographic
landmarks, such as fiducials [6], skull anatomy [7] or spine
anatomy landmarks [8]. After the initial setup of the
patient, when the tumor is localized and aligned, the radia-
tion is delivered. The treatment is modified in real time to
compensate for tumor movements. Several hundred treat-
ment beams are chosen out of a repertoire of more than
one thousand possible beam directions, using inverse
treatment planning. These beams are delivered in a non-
isocentric manner via small circular fields of varying size
and weighted with different monitor units (MU) [9].
To our knowledge, there have not been any other
reports of PD in patients undergoing intracranial treat-
ment with Cyberknife using Metal Oxide Semiconductor
Field Effect Transistor (MOSFET) dosimeters in the litera-
ture. However, there have been previous reports that have
studied PD in stereotactic radiosurgery and radiotherapy
treatments [10-14].
MobileMOSFET seems to be an appropriate dosimetry
system for in vivo measurements of low peripheral doses
during stereotactic radiosurgery/radiotherapy due to its
extremely small size (active area 0.04 mm
2), and its simple
and immediate read out, compared to the thermolumines-
cent dosimeter, and its accuracy at low doses [15-21].
The aim of this study was to evaluate PD at preselected
anatomical areas on the patient skin, corresponding to
radiosensitive organs using the MOSFET dosimeters and
to investigate the influence of the supplemental shielding,
the number of MU and the collimator size on the PD.
Methods
Patient information
In a study of 31 patients (fourteen (14) men and seven-
teen (17) women), that underwent intracranial
Cyberknife treatment at the Iatropolis Cyberknife Center
of Athens, PD was measured on four preselected areas
of the body, namely, the thyroid gland, the nipple, the
umbilicus and the pubic symphysis, using the mobile-
MOSFET dose verification system [22]. These measure-
ments took place in two different chronological periods,
before and after the shielding upgrade of the Cyberknife
unit; consequently ten patients were treated before the
installation of supplemental shielding and the remainder
after the upgrade. The MOSFET dosimeters were cali-
brated before their use under reference conditions.
The histological diagnoses of the patients are shown in
Table 1.
Cyberknife treatment
Tumor and organs at risk were visualized and delineated
on a volumetric CT study of each patient. During the
treatment planning process (Multiplan treatment plan-
ning system v.1.7), a finite set of non-isocentric, non-
coplanar treatment beams were created, producing the
final dose distribution (Figure 1). Each treatment beam is
correlated to a source point in a space around the
patient, through which the photon beam is directed
towards the target volume. Each source point is called a
node and the complete set of nodes constitutes the treat-
ment path [23]. For each patient one to three different
path sets (namely “even path head”, “1 path head” and
“short path head”) were utilized.
Different treatment field sizes, determined by inter-
changeable secondary circular collimators with dia-
meters of 5.0, 7.5, 10.0, 12.5, 15.0, 20.0, 25.0, 30.0, 35.0
and 60.0 mm (defined at a nominal treatment distance
of 80 cm) can be assigned to each treatment path. The
prescribed dose (TD) that is delivered to each patient is
from one to five fractions, using the Cyberknife system
of version 7.5, with a 600 MU/min linac.
Additional 19 mm (0.75 inch) tungsten shielding, was
installed by the manufacturer, at the point where the
primary collimator housing narrows to hold the
Table 1 Histologies of patients undergoing Cyberknife
treatment for intracranial or cranial lesions
HISTOLOGIES NUMBER OF CASES
Acoustic neuromas 7
Arterial venous malformations 2
Bone metastases 3
Brain metastases 6
Craniopharyngioma 1
Gliomas 3
Meningiomas 6
Nasopharyngeal carcinoma 1
Pituitary adenoma 1
T-lymphoma 1
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The purpose of the shielding was to reduce the leakage
radiation, leading to a decrease of PD.
For all treatments studied, the 6D Skull tracking method
is utilized, which can be used for both intracranial targets
and head and neck targets that can be considered fixed
relatively to the skull. Image registration is performed using
high contrast bone information contained within the entire
field of view. The resulting 2D transformations for each
orthogonal projection are combined and backprojected to
determine the 3D rigid transformation that aligns the posi-
tion and orientation of the skull in the treatment planning
CT image with the treatment delivery coordinate system
[7,23].
Results
Peripheral dose measurements
Results of the PD measurements in the four extracra-
nial sites, before and after shielding, are presented in
Tables 2, 3, 4, 5, 6, 7 and 8. The distance between the
point of measurement (the active area of MOSFET
dosimeters) and the treatment center was calculated
with respect to the room lasers. The distance ranged
from 14 to 22 cm for the thyroid gland, 29 to 42 cm
f o rt h en i p p l e ,5 2t o6 4c mf o rt h eu m b i l i c u sa n d6 3
to 88 cm for the pubic symphysis.
The first two columns of each table list the collimator
size used in each path of the treatment and the distance
of the dosimeter from the treatment center. The next
three columns list the PD in cGy, as a percentage of
MU (% PD in cGy/MU) and as a percentage of the pre-
scribed dose (% TD). Furthermore, the number of MU,
and the TD to the isodose line (IL) delivered in each
treatment, are listed.
The mean preshielding PD was 51.79 cGy (54.13 cGy),
13.31 cGy (7.61 cGy) and 10.07 cGy (5.77 cGy), in the
thyroid gland, the umbilicus and the pubic symphysis,
respectively, since in the preshielding measurements the
Figure 1 Illustration of the Cyberknife treatment beam geometry and of the treatment plan in axial, coronal, and sagittal views.
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was 38.40 cGy (33.13 cGy), 12.18 cGy (5.72 cGy), 10.94
cGy (4.83 cGy), and 8.69 cGy (3.90 cGy), in the thyroid
gland, the nipple, the umbilicus and the pubic symphy-
sis, respectively. The standard deviation of mean PD
measurements is given in parenthesis. Cyberknife mean
PD to extracranial sites ranged from 0.22% of the deliv-
ered number of MU, for the thyroid gland, to 0.04% for
the pubic symphysis.
Influence of the monitor units and collimator size on the
peripheral dose
The PD measurements as a function of the MU in the
four extracranial sites are presented in Figures 2, 3, 4
and 5. It is evident that the PD is proportional to the
number of MU and this correlation can be utilized to
estimate the PD, during intracranial treatment. In the
thyroid gland (Figure 2) a correlation between PD and
MU cannot be inferred, since the thyroid gland is
Table 2 Preshielding peripheral dose in the region of the thyroid gland, expressed as a percentage of the monitor
units and as a percentage of the prescribed dose
Collimator
size (mm)
Distance
(cm)
Preshielding
peripheral dose (cGy)
Preshielding peripheral
dose (%MU)
Preshielding peripheral
dose (%TD)
Monitor
units
Prescribed
dose (cGy)
Isodose
line (%)
12.5 20 5.00 0.12 0.25 4005 2000 84
10 20 6.48 0.12 0.32 5587 2000 75
20, 20, 20 22 15.22 0.13 0.76 11374 2000 75
5, 5, 5 20 23.01 0.13 1.15 18026 2000 75
7.5, 7.5, 15 16.5 35.38 0.17 1.97 20487 1800 79
10, 10, 15 14 164.90 0.69 6.60 23876 2500 75
20, 20, 20 14 40.55 0.16 1.62 25794 2500 67
5, 5, 5 18 59.43 0.22 3.30 27433 1800 76
7.5, 7.5, 15 19 35.73 0.13 1.99 28411 1800 75
7.5, 15, 25 14.5 132.15 0.33 5.29 39476 2500 70
MU: Monitor Units
TD: Prescribed Dose
Table 3 Postshielding peripheral dose in the region of the thyroid gland, expressed as a percentage of the monitor
units and as a percentage of the prescribed dose
Collimator
size (mm)
Distance
(cm)
Postshielding
peripheral dose (cGy)
Postshielding
peripheral dose (%MU)
Postshielding
peripheral dose (%TD)
Monitor
units
Prescribed
dose (cGy)
Isodose
line (%)
12.5 22 3.11 0.09 0.14 3483 2200 80
25 16 32.80 0.32 1.64 10355 2000 70
20, 20, 10 17 19.80 0.15 1.24 12911 1600 70
12.5, 12.5, 10 16 38.36 0.29 2.95 13271 1300 70
20, 20, 7.5 15 27.50 0.19 1.96 14289 1400 70
15 15 29.50 0.20 1.97 14621 1500 70
35 20 20.37 0.14 1.13 15061 1800 70
12.5, 12.5, 7.5 20 17.60 0.09 0.98 20391 1800 70
10 20 12.13 0.06 0.67 20789 1800 70
5, 5, 5 18 59.44 0.29 2.97 20798 2000 70
7.5 18 14.19 0.07 0.65 20969 2200 70
10, 10, 5 17 50.40 0.21 2.40 24249 2100 70
7.5, 15, 15 16.5 59.64 0.23 3.31 25696 1800 70
10, 12.5, 20 19 19.79 0.07 1.24 26656 1600 75
5, 5, 10 19 23.13 0.08 1.29 29230 1800 70
5, 10, 12.5 19 45.80 0.15 2.41 29833 1900 70
5, 5, 5 17 55.80 0.17 2.66 32202 2100 70
7.5, 12.5, 20 16 160.88 0.49 8.04 33130 2000 70
5, 7.5, 12.5 18 35.22 0.08 1.96 42177 1800 70
7.5, 12.5, 12.5 18 42.45 0.10 1.57 43623 2700 75
MU: Monitor Units
TD: Prescribed Dose
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Page 4 of 10located at different distances from the target in each
patient (from 14 to 22 cm), and at such small distances
from the target, even small changes in distances can
lead to relatively large changes in PD.
As seen in Figures 3, 4 and 5, for distances larger than
29 cm, where the nipple, the umbilicus and the pubic
symphysis are located, the major factor affecting the
correlation between the MU and the PD is the distance
of the anatomical region from the target. More
specifically, the reduction of the PD (expressed as a per-
centage of MU) between the anatomical regions of the
umbilicus and the pubic symphysis, can reach up to
22.54% and 23.39%, before and after shielding,
respectively.
In Figure 6 the effect of distance on the PD is demon-
strated in all the measurement data. It is evident that in
the thyroid region PD is greatly affected by the distance
while in the other regions it is almost constant.
Table 4 Postshielding peripheral dose in the region of the nipple, expressed as a percentage of the monitor units and
as a percentage of the prescribed dose
Collimator
size (mm)
Distance
(cm)
Postshielding
peripheral dose (cGy)
Postshielding
peripheral dose (%MU)
Postshielding
peripheral dose (%TD)
Monitor
units
Prescribed
dose (cGy)
Isodose
line (%)
12.5 38 1.34 0.04 0.06 3483 2200 80
25 29 6.04 0.06 0.30 10355 2000 70
20, 20, 10 33 7.89 0.06 0.49 12911 1600 70
12.5, 12.5, 10 31 7.22 0.05 0.56 13271 1300 70
20, 20, 7.5 31 7.96 0.06 0.57 14289 1400 70
15 31 7.75 0.05 0.52 14621 1500 70
35 37 8.49 0.06 0.47 15061 1800 70
12.5, 12.5, 7.5 36 11.84 0.06 0.66 20391 1800 70
10 38 11.45 0.06 0.64 20789 1800 70
5, 5, 5 32 11.24 0.05 0.56 20798 2000 70
7.5 35 10.54 0.05 0.48 20969 2200 70
10, 10, 5 29.5 11.67 0.05 0.56 24249 2100 70
5 31 13.65 0.06 0.76 24680 1800 80
7.5, 15, 15 32 14.79 0.06 0.82 25696 1800 70
10, 12.5, 20 33 13.24 0.05 0.83 26656 1600 75
5, 5, 10 34 12.24 0.04 0.68 29230 1800 70
5, 10, 12.5 35 13.20 0.04 0.69 29833 1900 70
5, 5, 5 33 16.02 0.05 0.76 32202 2100 70
7.5, 12.5, 20 32 20.12 0.06 1.01 33130 2000 70
5, 7.5, 12.5 34 23.10 0.05 1.28 42177 1800 70
7.5, 12.5, 12.5 42 26.07 0.06 0.97 43623 2700 75
MU: Monitor Units
TD: Prescribed Dose
Table 5 Preshielding peripheral dose in the region of the umbilicus, expressed as a percentage of the monitor units
and as a percentage of the prescribed dose
Collimator
size (mm)
Distance
(cm)
Preshielding
peripheral dose (cGy)
Preshielding peripheral
dose (%MU)
Preshielding peripheral
dose (%TD)
Monitor
units
Prescribed
dose (cGy)
Isodose
line (%)
12.5 58 2.15 0.05 0.11 4005 2000 84
10 58 2.83 0.05 0.14 5587 2000 75
20, 20, 20 62 7.67 0.07 0.38 11374 2000 75
5, 5, 5 59 11.64 0.06 0.58 18026 2000 75
7.5, 7.5, 15 59 12.62 0.06 0.70 20487 1800 79
10, 10, 15 58 16.00 0.07 0.64 23876 2500 75
20, 20, 20 55 19.35 0.08 0.77 25794 2500 67
5, 5, 5 56 17.40 0.06 0.97 27433 1800 76
7.5, 7.5, 15 55 16.68 0.06 0.93 28411 1800 75
7.5, 15, 25 50 26.75 0.07 1.07 39476 2500 70
MU: Monitor Units
TD: Prescribed Dose
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the PD, the mean PD of all paths that used the same colli-
mator size was calculated (after shielding). In Figures 7
and 8 it is evident that the increase of the collimator size
corresponds to an increase of the PD. This increase is
more apparent in regions near the tumor site, since PD is
predominantly due to patient scatter radiation which is
proportional to the scattering volume defined by the colli-
mator size, and becomes less significant at larger distances,
where PD is mainly attributed to head leakage and colli-
mator scatter.
Discussion
Peripheral dose measurements
SRT procedures deliver a very high dose per fraction
and as a result, the corresponding PD could be a limit-
ing factor for long term surviving patients.
The mean preshielding PD in the thyroid gland site, as
shown in Table 2 is 51.79 cGy and if expressed as a per-
centage of MU (or as a percentage of TD), is 0.22%
(2.32%), while the corresponding mean postshielding
result (Table 3) is 38.40 cGy, and if expressed as a
Table 6 Postshielding peripheral dose in the region of the umbilicus, expressed as a percentage of the monitor units
and as a percentage of the prescribed dose
Collimator
size (mm)
Distance
(cm)
Postshielding
peripheral dose (cGy)
Postshielding
peripheral dose (%MU)
Postshielding
peripheral dose (%TD)
Monitor
units
Prescribed
dose (cGy)
Isodose
line (%)
12.5 63 1.24 0.04 0.06 3483 2200 80
25 55 6.20 0.06 0.31 10355 2000 70
20, 20, 10 57 6.44 0.05 0.40 12911 1600 70
12.5, 12.5, 10 55 6.89 0.05 0.53 13271 1300 70
20, 20, 7.5 54 7.36 0.05 0.53 14289 1400 70
15 52 6.75 0.05 0.45 14621 1500 70
35 65 8.22 0.05 0.46 15061 1800 70
12.5, 12.5, 7.5 62.5 8.86 0.04 0.49 20391 1800 70
10 67 8.59 0.04 0.48 20789 1800 70
5, 5, 5 55 8.96 0.04 0.45 20798 2000 70
7.5 62 9.65 0.05 0.44 20969 2200 70
10, 10, 5 58.5 14.25 0.06 0.68 24249 2100 70
5 60 10.05 0.04 0.56 24680 1800 80
7.5, 15, 15 54 12.57 0.05 0.70 25696 1800 70
10, 12.5, 20 58 13.48 0.05 0.84 26656 1600 75
5, 5, 10 56 14.22 0.05 0.79 29230 1800 70
5, 10, 12.5 58 13.54 0.05 0.71 29833 1900 70
5, 5, 5 63 15.24 0.05 0.73 32202 2100 70
7.5, 12.5, 20 57 17.52 0.05 0.88 33130 2000 70
5, 7.5, 12.5 62 20.07 0.05 1.12 42177 1800 70
7.5, 12.5, 12.5 64 19.68 0.05 0.73 43623 2700 75
MU: Monitor Units
TD: Prescribed Dose
Table 7 Preshielding peripheral dose in the region of the pubic symphysis, expressed as a percentage of the monitor
units and as a percentage of the prescribed dose
Collimator
size (mm)
Distance
(cm)
Preshielding
peripheral dose (cGy)
Preshielding peripheral
dose (%MU)
Preshielding peripheral
dose (%TD)
Monitor
units
Prescribed
dose (cGy)
Isodose
line (%)
12.5 82 1.42 0.04 0.07 4005 2000 84
10 82 2.36 0.04 0.12 5587 2000 75
20, 20, 20 77 5.54 0.05 0.28 11374 2000 75
5, 5, 5 73 11.10 0.06 0.56 18026 2000 75
7.5, 7.5, 15 80 8.69 0.04 0.48 20487 1800 79
10, 10, 15 71 20.15 0.08 0.81 23876 2500 75
20, 20, 20 75 11.45 0.04 0.46 25794 2500 67
5, 5, 5 70 14.70 0.05 0.82 27433 1800 76
7.5, 7.5, 15 74 11.31 0.04 0.63 28411 1800 75
7.5, 15, 25 70 13.95 0.04 0.56 39476 2500 70
MU: Monitor Units
TD: Prescribed Dose
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(2.06%). The fact that these results are higher compared
to previous studies for both preshielding [11,13] and
postshielding [12,13] measurements can be attributed to
the fact that in these studies the thyroid gland has been
considered as a structure of avoidance and beams pas-
sing though it were disallowed. In the present study,
there was not such a constraint for the thyroid gland
during the treatment planning procedure, thus the
contribution of dose delivered by exiting beams
increases the PD in this region.
T h eb r e a s ti sc o n s i d e r e dt ob eo n eo ft h em o s ts e n s i -
tive organs to the carcinogenic effects of radiation,
which can be affected by scattered radiation. The mean
postshielding PD is 12.18 cGy according to Table 4,
which is in good agreement with Zytkovicz et al. [10],
and if expressed as a percentage of MU (or as a percen-
tage of TD) it is 0.05% (0.65%), along a cranial caudal
distance from 29 to 42 cm.
Table 8 Postshielding peripheral dose in the region of the pubic symphysis, expressed as a percentage of the monitor
units and as a percentage of the prescribed dose
Collimator
size (mm)
Distance
(cm)
Postshielding
peripheral dose (cGy)
Postshielding
peripheral dose (%MU)
Postshielding
peripheral dose (%TD)
Monitor
units
Prescribed
dose (cGy)
Isodose
line (%)
12.5 63 1.24 0.04 0.06 3483 2200 80
25 71 3.94 0.04 0.20 10355 2000 70
20, 20, 10 72 5.75 0.04 0.36 12911 1600 70
12.5, 12.5, 10 70.5 4.62 0.03 0.36 13271 1300 70
20, 20, 7.5 71 5.66 0.04 0.40 14289 1400 70
15 67 5.34 0.04 0.36 14621 1500 70
35 83 6.66 0.04 0.37 15061 1800 70
12.5, 12.5, 7.5 82 7.26 0.04 0.40 20391 1800 70
10 87 6.23 0.03 0.35 20789 1800 70
5, 5, 5 68 4.64 0.02 0.23 20798 2000 70
7.5 82 8.06 0.04 0.37 20969 2200 70
10, 10, 5 74 9.18 0.04 0.44 24249 2100 70
5 76 7.26 0.03 0.40 24680 1800 80
10, 12.5, 20 70 10.04 0.04 0.63 26656 1600 75
5, 5, 10 74 11.76 0.04 0.65 29230 1800 70
5, 10, 12.5 73 11.52 0.04 0.61 29833 1900 70
5, 5, 5 80 11.64 0.04 0.55 32202 2100 70
7.5, 12.5, 20 69 13.08 0.04 0.65 33130 2000 70
5, 7.5, 12.5 73.5 18.66 0.04 1.04 42177 1800 70
7.5, 12.5, 12.5 88 13.89 0.03 0.51 43623 2700 75
MU: Monitor Units
TD: Prescribed Dose
Figure 2 Peripheral dose (cGy) as a function of the monitor
units, in the region of the thyroid gland, before and after
shielding.
Figure 3 Peripheral dose (cGy) as a function of the monitor
units, in the region of nipple, after shielding.
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Page 7 of 10In the umbilicus site, PD could also have some poten-
tial deleterious effects on the fetus or embryo in the case
of a pregnant woman being treated with radiotherapy
[24,25]. Table 5 shows that the mean preshielding PD is
13.31 cGy and if expressed as a percentage of MU (or as
a percentage of TD) is 0.06% (0.63%) along a cranial cau-
dal distance from 50 to 62 cm. After shielding (Table 6),
the mean PD is 10.94 cGy and if expressed as a percen-
tage of MU (or as a percentage of TD) it is 0.05%
(0.59%), respectively, along a cranial caudal distance ran-
ging from 52 to 67 cm.
Finally, PD measurements in the pubic symphysis site
are presented in Tables 7 and 8. The mean preshielding
and the postshielding PD are 10.07 cGy and 8.69 cGy,
respectively, for a cranial caudal distance of 67 to 88 cm.
Mean PD expressed as a percentage of the number of
MU (and as a percentage of TD), are 0.05% (0.48%) and
0.04% (0.47%), before and after shielding, respectively.
Previously published studies for the same anatomical
regions report that the PD normalized to the delivered
number of MU is 0.055% [11] to 0.074% [13], for 53 cm
distance and 0.041% [11] and 0.049% [13] for distances
of 71.0 and 75.5 cm, respectively.
It is evident that the shielding upgrade in the Cyberknife
system creates a reduction in the PD in all extracranial
sites of measurement. This is due to the fact that, with the
placement of the shielding, an attenuation of leakage
radiation and scattered radiation through the collimator is
produced. The results showed that in the region of the
thyroid gland the reduction in PD is 21.30% while Chaung
et al [12] report a much greater reduction of 58.80%.
Therefore, as mentioned above, the development of
Cyberknife treatment plan without the thyroid gland to be
identified as a structure of avoidance causes a reduction of
the effect of shielding in this region.
More specifically, PD expressed as a percentage of the
delivered MU, shows a reduction of 23.69% and 24.54%,
in the umbilicus (a mean distance of 58 cm) and the
pubic symphysis (mean distance of 75 cm), respectively.
These results are in agreement with Chuang et al [12]
Figure 4 Peripheral dose (cGy) as a function of the monitor
units, in the region of umbilicus, before and after shielding.
Figure 5 Peripheral dose (cGy) as a function of the monitor
units, in the region of pubic symphysis, before and after
shielding.
Figure 6 Peripheral dose (cGy) as a function of distance for all
measurements, before and after shielding.
Figure 7 Peripheral dose, expressed as a percentage of
monitor units (%PD in cGy/MU), as a function of collimator
size (mm), in the region of thyroid gland.
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Page 8 of 10who show a 25% reduction at 53 cm (lower thorax) and
a 20% reduction at 71 cm (pelvis), while Di Betta et al.
[13] report that the reduction of the PD due to the
shielding upgrade could be up to 44% for the same ana-
tomical regions.
Influence of the monitor units and collimator size on the
peripheral dose
In this study, the anticipated reduction of PD with an
increasing distance from the treatment center is con-
firmed (Figure 6).
PD was expected to be proportional to the number of
MU. However, the correlation between the number of MU
and the PD can be utilized to roughly estimate the PD to a
specific anatomical region of interest (for distances larger
than 29 cm), during an intracranial treatment.
For distances larger than 29 cm, the PD expressed as a
percentage of MU tends to be constant, with the values
ranging as low as 0.02-0.08%, regardless of the existence of
shielding.
After the installation of shielding, the delivered PD, in
cases of treatments requiring 3000 to 15000 MU, ranged
from 1.34 to 8.49 cGy and from 1.24 to 8.22 cGy, to the
nipple and the umbilicus sites, respectively, according to
Figures 3 and 4. If the treatment plan requires 20000 to
30000 MU, the delivered PD ranged from 10.54 to 14.79
cGy and from 8.59 to 14.25 cGy, respectively. Finally, the
PD for treatment with more than 30000 MU up to 44000
MU ranged from 16.02 to 26.07 cGy to the nipple and
from 15.24 to 20.07 cGy, to the umbilicus.
As can be seen in Figure 5, presenting the results of
the pubic sypmhysis site, for a range of MU from 10000
to 15000, the delivered PD, ranged from 1.24 to 6.66
cGy. If the treatment plan requires 15000 to 30000 MU,
the delivered PD ranged from 4.64 to 11.76 cGy. Finally,
for a treatment plan which demands 30000 to 44000
MU, the corresponding values ranged from 11.64 to
18.66 cGy.
From Figures 7 and 8 it is evident that the increase of
the collimator size corresponds to an increase of the
PD, although a previous study [13] suggests that there is
no significant difference. More specifically, for the 20
mm collimator with respect to the 5 mm one, the
increase in PD can reach up to 196.88% close to the
thyroid gland, while it is only 63.38% close to the pubic
symphysis. On the other hand, as can be observed from
Figure 7, the increase of PD in the smallest collimator
could be attributed mainly to leakage radiation, which is
governed by the number of delivered MU, but also to
contributions from internally scattered radiation and
scattered radiation from the collimators. A more exten-
sive inquiry on the behaviour of the smallest size colli-
mator may be needed.
Estimation of the risk of induction of stochastic effects
According to the International Commission of Radiation
Protection [26] the nominal risk coefficient (cases per
10000 persons per Sv) for radiation induced cancer is 33
and 112, for the thyroid and the breast, respectively.
Making the assumption of considering the measured
values of PD as the organ dose, this corresponds to a
probability of secondary cancer appearance of about
0.127% for the thyroid and 0.136% for the breast. In the
case of the thyroid gland, which is close to the treat-
ment area, this probability could increase dramatically if
some of the exit beams pass through it. The risk for
inducing secondary cancers can be considered low for
the organs studied, by taking into account the existing
pathology of the patients undergoing Cyberknife treat-
ment. However, it should not be completely disregarded,
especially in long term surviving patients, who are being
treated for benign diseases or for curatively non meta-
static malignancies.
Conclusions
Since stereotactic radiosurgery/radiotherapy procedures
deliver a very high dose per fraction, the corresponding
PD is a limiting factor for the long term surviving
patients. Taking into consideration that more patients
are now being cured of benign and malignant diseases,
increased attention is required with respect to the late-
onset of secondary cancers and damage to other organs.
The PD measurements in this study, during intracranial
treatment with Cyberknife, show that the possible risk
of stochastic effect is low. However, a question that has
yet to be answered is whether the thyroid gland should
be a structure of avoidance in the treatment plan, espe-
cially if the treatment corresponds to a benign disease.
Weighting the effect of the number of MU and the
Figure 8 Peripheral dose, expressed as a percentage of
monitor units (%PD in cGy/MU), as a function of collimator
size (mm), in the regions of the nipple, umbilicus and pubic
symphysis.
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Page 9 of 10collimator size, can be effectively used during the opti-
mization procedure, in order to choose the most suita-
ble treatment plan that will deliver the maximum dose
to the tumor, while being compatible with the dose con-
straints for the surrounding organs at risk.
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